Skip to Main Content

Contribute Try STAT+ Today

Mylan

Most Read

Health By Elizabeth Preston

Negative descriptors are more likely to appear in health records of Black patients, study finds

Pharmalot By Ed Silverman

Analysis of JAMA and NEJM articles finds most authors failed to disclose conflicts

Health By Andrew Joseph

New data show those who recovered from Covid-19 were less likely than vaccinated to get infected during Delta wave

Health By Rachel Cohrs

Can mailing free Covid-19 tests turn Biden’s pandemic response around?

staffing

First Opinion By Dan Michelson

Covid-19 is no longer the biggest issue facing hospitals. Staffing is

Pharmalot By Ed Silverman

Pharmalittle: Disease ‘reversal’ startup launches with $3 billion and biotech vets; network distributed fake Gilead HIV meds

Sen. Wyden

Pharmalot By Ed Silverman

Senate Finance chair investigates Bristol Myers over an allegedly abusive overseas tax shelter

Blue RNA strand

Biotech By Adam Feuerstein

A new RNA-based drug startup launches with Rutgers science and money connections

All Coverage

Epipen

Pharmalot By Ed Silverman

Senators demand Mylan repay $50 million to the Pentagon for EpiPen

Pharmalot By Ed Silverman

Hospitals are itching for a share of the Mylan settlement over Medicaid rebates

advertisement

Epipen

Pharmalot By Ed Silverman

West Virginia AG vows to reject ‘woefully deficient’ Mylan deal with the feds

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Drug stocks hurt by fears that price hikes are abating

Alex Brandon/AP

Pharmalot By Ed Silverman

FTC seeks review of a court ruling on generic drug competition

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Senator to hold hearing on Mylan’s Medicaid settlement

Sanofi Auvi-Q

Pharmalot By Ed Silverman

An EpiPen alternative is about to return to your local pharmacy

Epipen

Pharmalot By Ed Silverman

EpiPen prescriptions continue to climb, but market share dropped

Pharmalot By Ed Silverman

Elizabeth Warren criticizes feds for a ‘shamefully weak’ deal with Mylan

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month

The Pharmalot View By Ed Silverman

Health officials should reject latest gambit by EpiPen maker to feed at the public trough

Heather Bresch

Pharmalot By Ed Silverman

Mylan to pay $465 million to settle claims of shortchanging Medicaid

EpiPen

Pharmalot By Ed Silverman

Mylan overcharged Medicaid for EpiPen for years, despite warnings

Injection

First Opinion By Jennifer Brokaw

Cheap EpiPen alternative risks patients’ lives. I’ve seen it myself

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Chicago can proceed with lawsuit against opioid drug makers

EpiPen

Pharmalot By Ed Silverman

Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid

Epipen

Pharmalot By Ed Silverman

Lawmakers ask Justice Department to probe Mylan over Medicaid rebates

EpiPen Pricing

First Opinion By James R. Baker Jr.

EpiPen pricing controversy reflects larger issues in pharma industry

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Most Californians support proposed law to limit drug prices

Heather Bresch

The Pharmalot View By Ed Silverman

Behind the grandstanding, Congress may have taken a key step to clarifying drug prices

Heather Bresch

Business By Ike Swetlitz

Lawmakers lash out at Mylan over EpiPen profit revision

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Mylan’s parent bloggers feel jilted thanks to price hikes

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Congress probes FDA’s Office of Criminal Investigations

Epipen

Business By Ike Swetlitz

Anger at EpiPen prices channeled at Mylan CEO in congressional hearing

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Mylan CEO’s mom helped push EpiPen to schools